Ironwood Pharmaceuticals annual debt-to-ebitda ratio
2019
2020
2021
2022
2024
2025
Ironwood Pharmaceuticals Debt-to-EBITDA Ratio Growth & History (IRWD)
Ironwood Pharmaceuticals's debt-to-ebitda ratio was 0.13 for fiscal 2025.
View full Ironwood Pharmaceuticals company overviewIronwood Pharmaceuticals annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.13 | −2.14 | −94.21% |
| 2024 | 2024-12-31 | 2.27 | — | — |
| 2022 | 2022-12-31 | 1.65 | 0.12 | +7.60% |
| 2021 | 2021-12-31 | 1.54 | −1.59 | −50.84% |
| 2020 | 2020-12-31 | 3.12 | −0.31 | −8.93% |
| 2019 | 2019-12-31 | 3.43 | — | — |
Ironwood Pharmaceuticals quarterly debt-to-ebitda ratio
Q2.18
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.05 | −2.82 | −98.24% |
| Q1 2026 | 2026-03-31 | 0.06 | −3.89 | −98.43% |
| Q4 2025 | 2025-12-31 | 0.13 | −2.14 | −94.21% |
| Q3 2025 | 2025-09-30 | 1.72 | −0.41 | −19.44% |
| Q2 2025 | 2025-06-30 | 2.87 | 1.00 | +53.65% |
| Q1 2025 | 2025-03-31 | 3.95 | — | — |
| Q4 2024 | 2024-12-31 | 2.27 | — | — |
| Q3 2024 | 2024-09-30 | 2.13 | — | — |
| Q2 2024 | 2024-06-30 | 1.87 | — | — |
| Q1 2023 | 2023-03-31 | 1.64 | −0.54 | −24.91% |
| Q4 2022 | 2022-12-31 | 1.65 | 0.12 | +7.60% |
| Q3 2022 | 2022-09-30 | 1.73 | −0.36 | −17.20% |
| Q2 2022 | 2022-06-30 | 1.76 | −0.50 | −22.12% |
| Q1 2022 | 2022-03-31 | 2.18 | −0.41 | −15.84% |
| Q4 2021 | 2021-12-31 | 1.54 | −1.59 | −50.84% |
| Q3 2021 | 2021-09-30 | 2.09 | −1.00 | −32.22% |
| Q2 2021 | 2021-06-30 | 2.26 | −0.40 | −14.96% |
| Q1 2021 | 2021-03-31 | 2.59 | −0.21 | −7.54% |
| Q4 2020 | 2020-12-31 | 3.12 | −0.31 | −8.93% |
| Q3 2020 | 2020-09-30 | 3.09 | −0.52 | −14.32% |
| Q2 2020 | 2020-06-30 | 2.65 | — | — |
| Q1 2020 | 2020-03-31 | 2.80 | — | — |
| Q4 2019 | 2019-12-31 | 3.43 | — | — |
| Q3 2019 | 2019-09-30 | 3.60 | — | — |
| Q2 2018 | 2018-06-30 | 13.09 | — | — |
Ironwood Pharmaceuticals debt-to-ebitda ratio trends
Over the last five fiscal years, Ironwood Pharmaceuticals's debt-to-ebitda ratio decreased from 3.12 to 0.13, a change of −2.99. The latest reported quarter, Q2 2026, shows 0.05.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ironwood Pharmaceuticals source filings ↗